10x Genomics (TXG) Change in Accured Expenses (2018 - 2026)

10x Genomics' Change in Accured Expenses history runs 9 years deep, the most recent figure standing at -$6.1 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 241.74% year-over-year to -$6.1 million; the TTM figure through Mar 2026 stood at -$15.6 million (down 466.02% YoY), while the FY2025 annual figure was -$5.2 million, up 59.54% from the prior year.
• Change in Accured Expenses came in at -$6.1 million for Q1 2026 at 10x Genomics, down from $4.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $15.6 million in Q2 2023 to a low of -$15.1 million in Q1 2023.
• A 5-year average of -$1.4 million and a median of $547000.0 in 2024 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses surged 1091.03% in 2022 and tumbled 1419.93% in 2025, its largest moves.
• 10x Genomics' Change in Accured Expenses stood at $6.5 million in 2022, then slumped by 281.41% to -$11.8 million in 2023, then soared by 137.31% to $4.4 million in 2024, then grew by 8.8% to $4.8 million in 2025, then plunged by 228.21% to -$6.1 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$6.1 million, $4.8 million, and -$7.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison